Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)

NCT07113522 is registered in ClinicalTrials.gov with Mirador Therapeutics, Inc. as lead sponsor.

NCT NCT07113522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07113522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics With Multiple Therapies in Participants With Active Crohn's Disease or Active Ulcerative Colitis (ASCEND-IBD)
Lead sponsor
Mirador Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
June 26, 2025
Completion date
February 4, 2028
Enrollment
140 (estimated)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, inflammatory bowel disease (ibd), ulcerative colitis (uc)